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MODIFIED FOODS IN THE UNITED STATES
Participants: L. Val Giddings, Gregory Jaffe & David Hegwood
Moderated by Kathleen Hart
 Cite as: L. Val Giddings, et al., Symposium: Panel Remarks on Regulating Genetically   
 Modified Foods in the United States, 10 RICH J.L. & TECH. 11 (2003), at http://law.richmond. 
 edu/jolt/v10i2/article11.pdf.
Ms. Kathleen Hart: {1}  Thank you all.  In my opinion, containment of pharmaceutical GM crops  
   is essential and hard to do. The USDA just recently came up with some new  
   guidelines for genetically modified pharm plants, but how can the public 
   have an input into what’s going on if they don’t even know where the crops  
   are growing, or what’s in the crops, because this is protected as confidential  
   business information?  Should the public have a say? How would we   
   accomplish--giving the public a say about whether they want genetically 
   engineered wheat, even aside from the export issues. Third, I understand GE  
   salmon is very close to being approved and released. That’s a containment  
   issue of another kind. The fourth issue is that there are all kinds of organisms
    that don’t even fall under  EPA, USDA, or FDA jurisdiction, such as GE   
   mosquitoes, and so forth. So, is there some way that you would want to propose  
   changes to the regulations that would help bring the public into the debate?  A  
   couple minutes each.
Mr. Gregory Jaffe: {2}  Well I’m not going to tackle all those, it’s too much, but my view on
   transparency and public participation is that regulatory processes should be  
   open.  I do also believe that there is genuine confidential business information.
      To the extent that some information is genuine confidential business   
   information and qualifies under the case law that exists out there, it should be  
   protected.  In some cases that may be the test plot where something is grown.   
   That doesn’t mean you couldn’t find out the state it’s grown in or the county it’s  
   grown in; that might not be confidential.  
   {3}  Similarly, in some cases the drug or the specific product may be 
   confidential.  A lot of these things are patented; a lot of those things are out
   there.  One of the things about something being confidential business 
   information is that it’s the traits you get from the company that are protected.   
   My criticism of the system is that I think the government has taken at face value 
   a lot of the companies’ claims of CBI.  The way the system is supposed to work, 
   the government is supposed to question those and only protect what is truly  
   confidential.  
   {4}  My answer to your question is, if information is truly confidential then,  
   yes, the company should have a right to keep it confidential, but the agency  
   should be looking closely at that and they should be doing it based on the case  
   law that exists out there.  As to your other remarks, such as about the wheat,
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   I agree with David Hegwood.  Our regulatory system and agencies like FDA  
   should deal with risks; they should deal with the food safety risks.  That’s what  
   we want them to do, be an independent agency that looks at the risks.  
   {5}  Other social issues, marketing issues, other kinds of things, I agree that  
   those are big concerns and they should be addressed but they shouldn’t be   
   addressed by regulatory agencies that are addressing safety concerns.  I don’t  
   think you should mix jurisdictions.  I think one of the things that our society has  
   to figure out through Congress and the Administration is, what are the forums to 
             address those other social, ethical, or other factors?  I’m one who’s not advocating  
   FDA to step in to do that.
Mr. David Hegwood: {6}  Well, I will briefly address the issue of pharmaceutical field trials.  I think 
   the first point to emphasize is these are field trials.  This is research and 
   development.  These are not commercialized products.  These are not products  
   that humans are going to consume.  This is strictly research and development at 
   this stage.  So if the public is saying, “We want to know where these are grown 
   and what they are,” I guess I would have to ask “Why do you want to know?”  
   Is it because you’re afraid you’re going to be consuming them?  If you are, I 
   can tell the answer is no, you’re not.  The objective of our regulatory system 
   is to ensure that you don’t consume the goods.  That’s the whole purpose.  So, at 
   some point should there be public input into the process before these things 
   are commercialized, if and when they are ever commercialized?  Absolutely, 
   and it will happen.  The process is in place, that’s what the regulations say.  
   Again, as Greg Jaffe said, you have to respect the confidential information.  This 
   is not a new issue; this is something we’ve been dealing with for as long as we’ve 
   had business.
Dr. Val Giddings: {7}  Yes, I’d like to take all of the questions, but I’m not sure I can remember 
   them all.  First, I’ll point out that it is not true that we don’t know where these  
   things are being grown.  Confidential business information sometimes protects  
   the specific cooperator and the individual farmer who is growing these crops,
   but even when that claim is made, the county in which this is grown is specified  
   several places in the environmental assessment by the companies in each and  
   every request for permission to grow this stuff.  This is on record; you don’t have  
   to believe me.  Go to the USDA website, and you can download these tables.   
   You can spend the rest of your natural life, or a good portion of it, downloading  
   and reviewing this information.
   {8}  On to the salmon issue and containment.  Dr. Hoover has said there have  
   not been any surprises to date on the transgenic crops produced for food use and
    so forth – and that’s true.  He did see, however, assert a surprise with the salmon.   
   The one surprise that has come up with this transgenic salmon, after extensive  
   analysis, has been that it contains a slightly higher yet significant concentration of
    the omega three fatty acids that has everyone encouraged to eat salmon.  The only 
   surprises that I know of so far have been positive surprises.
   {9}  On the issue of containment, the transgenic salmon that are being developed  
   are number one, all female, and number two, sterile.  Okay, so these salmon, even  
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   if they are put in commerce, and even if they are released in ocean pens which
   is conventional today, these salmon represent a substantial and significant   
   improvement in the level of safety over and above what we already see with the  
   existing salmon farming technologies.
   {10}  So that highlights on a very important question to focus on when we’re  
   talking about safety of crops and foods.  The right question to ask isn’t how safe  
   is it or what is the level of safety in terms what probabilities or  consequence  
   A, B, or C.  The question that is really most useful to ask is how does the level  
   of safety for this new product compare to the level of safety that we already  
   accept as routine with the existing products?  Without exception, in each and  
   every case to date, the answer to that question for crops and foods produced by a
    biotech method are at least as safe and in numerous cases they are safer   
   than those that we already now enjoy.
 
Ms. Kathleen Hart: {11}  Thank you all for your participation.
